Cannabis Law Report

AUGUST 13, 2021

Instead, it is hypothesised that SalA indirectly influences the cannabinoid system, as well as being an allosteric modulator of the µ opioid receptor. Clinically, there are published reports of the potential benefits of Salvia divinorum in the treatment of TRD. BERLIN, Aug.

Conditions 105

Conditions Research and Development Clinical Trials Treatment 105

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. The cannabis research problem. Despite the massive amount of research publications that come out year over year, many of these studies face one or more research design limitations.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

Cannabis Law Report

JULY 8, 2021

Seeks To Identify Novel Cannabinoids For Therapeutic Use. The Company expects to finalize the agreement with the research institute and commence studies by Fall 2021. The intended purpose of these studies is to provide data that will feed into the cbdMD Therapeutics research pipeline. CHARLOTTE, N.C.–(BUSINESS

Research and Development 85

Research and Development Pets Cannabinoids eCommerce 85

Cannabis Law Report

AUGUST 23, 2021

Oxford Cannabinoid Technologies Holdings plc. Strict cash management controls are in operation across all areas of expenditure, whereby all budgeted central costs have been reviewed with measures agreed to reduce these wherever possible, in order to maximise the Group’s financial resources available for its drug development programmes.

Cannabinoids 98

Cannabinoids Research and Development Clinical Trials Packaging 98

Cannabis Law Report

SEPTEMBER 2, 2021

The use of cannabinoids in the treatment of medical conditions offers major opportunities and challenges to anyone operating in the space. Prohibition Partners has identified at least 30 late-stage clinical trials using cannabinoid therapeutics, any of which will probably have a large impact on the medicinal cannabis space.

Pharmaceutical 105

Pharmaceutical Clinical Trials Research and Development Cannabinoids 105

Project CBD

NOVEMBER 11, 2023

NM: As someone who has been researching cannabis for decades, how do you feel about the current legalization situation worldwide and in Japan, in particular? Dr. Andrew Weil: I think the trend very clearly is that in most developed countries, cannabis is being made legal first for medical uses and then also for recreational uses.

Medicine 306

Medicine Research and Development Pharmaceutical Cannabis 306

Cannabis Law Report

JULY 27, 2021

.–(BUSINESS WIRE)– Realm of Caring (RoC) , a nonprofit dedicated to cannabinoid research, has appointed Nicolas Schlienz, Ph.D., as its Research Director, a new role in the organization’s leadership. plan to conduct a controlled clinical trial to further understand the effects of CBD in epilepsy treatment.

Data 81

Data Epilepsy Research and Development Clinical Trials 81

Cannabis Law Report

SEPTEMBER 10, 2021

The announcement of a partnership between Clerkenwell Health and Octarine Bio signals a momentous time for the growth and development of the European psychedelic ecosystem. Clerkenwell Health is a psychedelic specialist clinical research organisation, based in the UK, backed with investment from VC Fund Vine Ventures, and Angel investors.

Research and Development 104

Research and Development Clinical Trials Therapy Environment 104

Cannabis Law Report

NOVEMBER 12, 2021

Neil Mahapatra is a co-founder of the Oxford Cannabinoid Technologies (OCT) which floated on the LSE in the May this year, he is also founder of UK venture capital business Kingsley Capital Partners (KCP). Oxford Cannabinoid Technologies’ Shares Fall A Further 20% As Chairman Stands Down Following Market Rule Breach.

Cannabinoids 98

Cannabinoids Clinical Trials Research and Development Pharmaceutical 98

The Cannigma

APRIL 12, 2023

CBN has made headlines and claimed shelf space as the next best cannabinoid for sleep. What this means for CBN research These results are, in a word, impressive. While CBN is often marketed as “the sleep cannabinoid ,” the reality is more complicated. These marketing claims are abundant, yet most of the evidence is anecdotal.

Sleep 133

Sleep Data Tincture Research and Development 133

Cannabis Law Report

AUGUST 10, 2021

Shanti”), and all its assets focused on psychedelic MDMA-based drug development. This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. billion in 2030.

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

Veriheal

MAY 3, 2022

A recent study , funded by the National Institute on Drug Abuse (NIDA) and published in JAMA Network Open , reported a correlation between obtaining a medical marijuana (MMJ) card and developing CUD. Despite being published in a reputable journal, there are questions about the legitimacy of the research. Clinical Trial Sample Size.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

CannaMD

APRIL 23, 2020

They describe their goal as “marrying cutting edge cannabis cultivation with biopharmaceutical research and development.” Their state-of-the-art, 28,000 square-foot cultivation lab and custom “tissue propagation” techniques provide raw materials for ongoing research studies.

Clinical Trials 116

Clinical Trials Research and Development Marijuana Treatment 116

Cannabis Law Report

JULY 26, 2021

OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has appointed Praveen Tyle, Ph.D., SAN DIEGO, CA, July 26, 2021 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. About Skye Bioscience.

Research and Development 105

Research and Development Clinical Trials Pharmaceutical Cannabinoids 105

The Cannigma

DECEMBER 14, 2021

Hexahydrocannabinol (HHC), which was patented in the late 1940s as a “therapeutic substance having marihuana activity,” is a cannabinoid that’s growing in popularity and availability. HHC was synthesized in Adams’ laboratory as part of research to understand the active compounds in the cannabis plant. HHC metabolism.

Research and Development 116

Research and Development Clinical Trials Cannabinoids THC 116

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Medicinal Marijuana Association

AUGUST 27, 2019

Extensive research in the United States and England on cannabis in the 1930s came to a halt with the beginning of World War II and did not pick up again afterwards due to the various laws and regulations that classified the plant as a drug.Legal issuescontinued to inhibit serious study until half a century ago, when Prof.

Research and Development 66

Research and Development Clinical Trials Patients Epilepsy 66

CannaMD

MAY 25, 2021

In recent years, research has revealed that two of marijuana’s two major cannabinoids — THC and CBD — can interact with the human endocannabinoid system to influence bone healing and regeneration. At the four week mark and beyond, however, this trend reversed, resulting in an increase in new bone development.

Marijuana 111

Marijuana Research and Development Clinical Trials THC 111

Veriheal

JUNE 30, 2023

A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

AUGUST 2, 2021

OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. TEL AVIV, Israel , Aug.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD. 561-627-9455.

DEA 51

DEA Clinical Trials THC Research and Development 51

MMJ Recs

JULY 9, 2024

In this article, we explore how medical marijuana for multiple sclerosis symptoms helps patients, with its diverse cannabinoid components, alleviate MS symptoms, and enhance the quality of life for patients. ” Other cannabinoids, like cannabinol (CBN) and cannabigerol (CBG), also contribute to the plant’s medicinal benefits.

Marijuana 111

Marijuana Treatment Cannabinoids Patients 111

Puff Puff Post

MARCH 10, 2020

“We are very pleased with the rapid completion of enrollment achieved by the team at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands,” said Alexandra Mancini, InMed’s Senior Vice President of Clinical Development & Regulatory Affairs. For more information, visit www.inmedpharma.com.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Veriheal

OCTOBER 13, 2020

Ethan Russo theorized that IBS may present itself in an individual as a result of a deficiency in the body’s’ own cannabinoid chemicals, which are located in the endocannabinoid system (the ECS). More research and clinical trials are needed to fully understand how cannabinoids help those suffering from GI pathologies.

Digestion 124

Digestion Treatment Conditions Research and Development 124

Veriheal

JANUARY 28, 2022

A team of researchers at Tel Aviv University in Tel Aviv, Israel, led by Ph.D. The researchers administered cannabis oil to animal models, which had a mutation of the Shank3 gene that “is associated with about 1 percent of autism cases.” About the Study: Autism and Cannabis. Important Findings for Autism Patients and Families.

Oil 104

Oil THC Research and Development Treatment 104

SpeedWeed

JULY 23, 2021

Denver is expanding Alzheimer’s research through the efforts of local company MedPharm. . The company plans to move forward with research efforts through a special Schedule I Researcher Licenses given specifically to the company by the Drug Enforcement Administration. Denver Company Moves Forward with Research License .

Clinical Trials 52

Clinical Trials Research and Development DEA Cannabinoids 52

The Cannigma

JUNE 23, 2022

While CBG (cannabigerol) has been hailed ‘the mother of all cannabinoids,’ it’s time to reveal the true heir to the throne – cannabigerolic acid, or CBGA. This cannabinoid has only recently been studied, and future studies will certainly divulge its exact importance. What is the difference between CBG and CBGa? What does CBGA do?

Cannabinoids 113

Cannabinoids Research and Development Clinical Trials Extraction 113

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma’s objective is to create and leverage a proprietary drug development platform in collaboration with an artificial intelligence and machine learning group to identify new bioactive compounds within the cannabis plant that interact with certain gene targets responsible for specific disease states and conditions.

Clinical Trials 40

Clinical Trials Research and Development Pharmaceutical Events 40

Puff Puff Post

JANUARY 1, 2020

As cannabis legalisation spreads, research has found considerable use in for cannabis in medicine. One particularly promising area of research is in the treatment of cancer. Cannabinoids even alleviate certain types of pain that opiates don’t always treat well. Approved Cannabinoid-Based Medications.

Treatment 49

Treatment Clinical Trials Research and Development Cannabinoids 49

Puff Puff Post

JANUARY 13, 2020

Now that retailers broadly sell CBD oil, it offers a number of challenges and opportunities to medical researchers. Generally speaking, 99 cent stores sell CBD that doesn’t have its terpenes or other cannabinoids measured. Preliminary Research on CBD Oil. CBD is the most abundant active ingredient within the CBD oil.

CBD 52

CBD Clinical Trials Research and Development Oil 52

Puff Puff Post

JANUARY 13, 2020

Now that retailers broadly sell CBD oil, it offers a number of challenges and opportunities to medical researchers. Generally speaking, 99 cent stores sell CBD that doesn’t have its terpenes or other cannabinoids measured. Preliminary Research on CBD Oil. CBD is the most abundant active ingredient within the CBD oil.

CBD 52

CBD Clinical Trials Research and Development Oil 52

Cannabis Law Report

MARCH 25, 2020

OTCQB: AXIM) (“AXIM® Biotech” or “AXIM”) has completed the acquisition of leading oncology research and development company Sapphire Biotech, Inc. (“Sapphire”). Valencia has stewarded Sapphire in the development of its unique patent-pending pipeline.

Research and Development 45

Research and Development Supply Chain Pharmaceutical Clinical Trials 45

The Cannigma

FEBRUARY 2, 2021

In light of these results, the researchers behind the survey say that physicians should pay special consideration to these aspects when advising patients on their medical cannabis treatment options. More than 8 percent of those surveyed also reported already using cannabinoids, with 54 percent noting a beneficial clinical effect.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Cannabis Law Report

JUNE 17, 2021

This landmark investment and strategic transaction solidifies Brains’ position as one of the leading pharmaceutical companies in the cannabinoid (CBD) sector. Brains is one of a few companies in the world producing CBD as an API for pharmaceutical applications, research, development, and clinical trials.

Pharmaceutical 105

Pharmaceutical Clinical Trials Research and Development Events 105

Cannabis Law Report

JANUARY 4, 2022

Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for the clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid Use Disorder. ABOUT ANANDA SCIENTIFIC.

Clinical Trials 40

Clinical Trials Treatment Research and Development Media 40

Puff Puff Post

OCTOBER 3, 2019

Previous success from treating epilepsy with Cannabinoids now motivates doctors to investigate the plant’s effectiveness in treating symptoms of autism. In a 47 acre greenhouse – close to the size of 42 football fields – GW is developing and delivering strains of medicinal cannabis.

Research and Development 94

Research and Development Epilepsy Clinical Trials Treatment 94